BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 8093555)

  • 21. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S; Miller G; Schally AV
    Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
    Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):248-52. PubMed ID: 6141560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.
    Jungwirth A; Pinski J; Galvan G; Halmos G; Szepeshazi K; Cai RZ; Groot K; Vadillo-Buenfil M; Schally AV
    Eur J Cancer; 1997 Jun; 33(7):1141-8. PubMed ID: 9376196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.
    Jungwirth A; Schally AV; Halmos G; Groot K; Szepeshazi K; Pinski J; Armatis P
    Cancer; 1998 Mar; 82(5):909-17. PubMed ID: 9486581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists.
    Redding TW; Schally AV
    J Endocrinol; 1990 Aug; 126(2):309-15. PubMed ID: 2144873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement.
    Zalatnai A; Schally AV
    Int J Pancreatol; 1989 Mar; 4(2):149-60. PubMed ID: 2566638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T; Pinski J; Radulovic S; Schally AV
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice.
    Radulovic S; Nagy A; Szoke B; Schally AV
    Cancer Lett; 1992 Mar; 62(3):263-71. PubMed ID: 1317746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.
    Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1983 Mar; 80(5):1459-62. PubMed ID: 6219395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Membrane receptors for peptides in experimental and human pancreatic cancers.
    Fekete M; Zalatnai A; Comaru-Schally AM; Schally AV
    Pancreas; 1989; 4(5):521-8. PubMed ID: 2573055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.